Vanda Pharmaceuticals Inc., a leading biopharmaceutical company, has filed a lawsuit against federal drug regulators over the approval of a generic version of their endogenous sleep drug, Hetlioz. The lawsuit alleges that the Federal Drug Administration (FDA) “turned a blind eye to” significant issues identified within the generic drug’s studies.
This legal challenge comes as a critical moment, as the FDA’s approval of the generic version directly threatens Vanda’s hold on the market for Hetlioz, an integral product in the drug company’s lineup. The alleged issues in the generic drug’s studies, as referenced by Vanda, could pose significant questions about the FDA’s drug review process and raise the need for further scrutiny of generic drug approvals.
For more in-depth coverage of the unfolding legal battle between Vanda Pharmaceuticals and the FDA, detailed coverage of the case is available on
Law360.